The 100 most influential manuscripts in gastric cancer: A bibliometric analysis
- 1 April 2016
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 28, 83-90
Abstract
Bibliometric analysis highlights the key topics and publications which have shaped the understanding and management of Gastric cancer. Here the 100 most cited manuscripts in the field of gastric cancer (GC) are analysed. The Thomson Reuters Web of Science database with the search terms 'gastric cancer' or 'gastric carcinoma' or 'stomach cancer' or 'stomach carcinoma' or 'gastroscopy' was used to identify all English language full manuscripts for the study. The 100 most cited papers were further analysed by topic, journal, author, year and institution. 122,616 eligible papers were returned and the median (range) citation number was 417 (2893-299). The most cited paper (by Parsonnet) focused on H.Pylori risk and gastric cancer (2893 citations). Cancer Research published the highest number of papers (n = 13, 6901 citations) and The New England Journal of Medicine (NEJM) had the most citations (n = 8, 9358 citations). The country and year with the greatest number of publications were the USA (n = 29), and 1998 (n = 10). The most ubiquitous topic was the pathology of gastric cancer (n = 57) followed by aetiology of gastric cancer (n = 47), and basic science of gastric cancer (n = 44). The most cited manuscripts highlighted in this study describe the science related to the pathogenesis of GC including surgery and regimens that have resulted in the contemporary understanding and treatment of GC. This work provides the most influential references related to GC and serves as a guide as to what makes a citable paper.Keywords
Funding Information
- the Welsh Government
This publication has 86 references indexed in Scilit:
- The 100 classic papers of orthopaedic surgeryThe Journal of Bone and Joint Surgery. British volume, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cellsInternational Journal of Cancer, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Helicobacter pyloriInfection and the Development of Gastric CancerNew England Journal of Medicine, 2001
- Interleukin-1 polymorphisms associated with increased risk of gastric cancerNature, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995